OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 57
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 57
Showing 1-25 of 57 citing articles:
Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives
Jiahao Li, Gong Chen, Haiting Zhou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5489-5489
Open Access | Times Cited: 20
Jiahao Li, Gong Chen, Haiting Zhou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5489-5489
Open Access | Times Cited: 20
FGF-based drug discovery: advances and challenges
Gaozhi Chen, Lingfeng Chen, Xiaokun Li, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 4
Gaozhi Chen, Lingfeng Chen, Xiaokun Li, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 4
Sialoblastomas With Solid Pattern Have FGFR2 Mutations and an Unfavorable Prognosis
Xiaoli Jia, Nan-Nan Leng, Min Wang, et al.
The American Journal of Surgical Pathology (2025)
Closed Access | Times Cited: 1
Xiaoli Jia, Nan-Nan Leng, Min Wang, et al.
The American Journal of Surgical Pathology (2025)
Closed Access | Times Cited: 1
<i>FGFR </i> Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy
Mark F Sabbagh, Tyler Janovitz, Dora Dias-Santagata, et al.
Thyroid (2024) Vol. 34, Iss. 9, pp. 1137-1149
Closed Access | Times Cited: 4
Mark F Sabbagh, Tyler Janovitz, Dora Dias-Santagata, et al.
Thyroid (2024) Vol. 34, Iss. 9, pp. 1137-1149
Closed Access | Times Cited: 4
Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting
Lu Sun, Jia Ma, Yajuan Zhou, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Lu Sun, Jia Ma, Yajuan Zhou, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
An FGF2-Derived Short Peptide Attenuates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting Collagen Deposition and Epithelial–Mesenchymal Transition via the FGFR/MAPK Signaling Pathway
Mengwei Wang, Yuanmeng Sun, Yanzhi Zhao, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 517-517
Open Access
Mengwei Wang, Yuanmeng Sun, Yanzhi Zhao, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 517-517
Open Access
Unveiling Targets and Resistance in FGFR-Altered Cancers
C. Benedikt Westphalen
Annals of Oncology (2025)
Closed Access
C. Benedikt Westphalen
Annals of Oncology (2025)
Closed Access
Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer
Yanlong Zhang, Hanbing Wang, Yutao Wei, et al.
(2025)
Open Access
Yanlong Zhang, Hanbing Wang, Yutao Wei, et al.
(2025)
Open Access
Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer
Yanlong Zhang, Hanbing Wang, Yutao Wei, et al.
(2025)
Open Access
Yanlong Zhang, Hanbing Wang, Yutao Wei, et al.
(2025)
Open Access
Five Key Criteria for Identifying Optimal Therapeutic Targets in Protein‐Mediated Diseases
Mohammed Baqur S. Al‐Shuhaib, Jafar M. B. Al‐Shuhaib
ChemistrySelect (2025) Vol. 10, Iss. 4
Closed Access
Mohammed Baqur S. Al‐Shuhaib, Jafar M. B. Al‐Shuhaib
ChemistrySelect (2025) Vol. 10, Iss. 4
Closed Access
Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications
Taroh Satoh, Philippe Barthélémy, Lucia Nogová, et al.
European Journal of Cancer (2025), pp. 115262-115262
Closed Access
Taroh Satoh, Philippe Barthélémy, Lucia Nogová, et al.
European Journal of Cancer (2025), pp. 115262-115262
Closed Access
Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance
Yazhou Wang, Yihong Zhang, Jinxin Liu, et al.
Journal of Medicinal Chemistry (2025) Vol. 68, Iss. 3, pp. 3886-3899
Closed Access
Yazhou Wang, Yihong Zhang, Jinxin Liu, et al.
Journal of Medicinal Chemistry (2025) Vol. 68, Iss. 3, pp. 3886-3899
Closed Access
Rationally Designed Cell Membrane Biomimetic Biosensing Platform for the Binding Analysis of Drugs with Intracellular Kinase Domain of Epidermal Growth Factor Receptor
Xia Liu, Quan Feng, Qi Hu, et al.
Analytical Chemistry (2025)
Closed Access
Xia Liu, Quan Feng, Qi Hu, et al.
Analytical Chemistry (2025)
Closed Access
Preparation and Characterization of an Engineered FGF1 Conjugated to 161Tb for Targeting of FGFRs
Linlin Song, Michał Kostas, Jon K. Laerdahl, et al.
ACS Omega (2025) Vol. 10, Iss. 6, pp. 5730-5743
Open Access
Linlin Song, Michał Kostas, Jon K. Laerdahl, et al.
ACS Omega (2025) Vol. 10, Iss. 6, pp. 5730-5743
Open Access
Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease
R. Pichler, Nils C. H. van Creij, José Daniel Subiela, et al.
Actas Urológicas Españolas (English Edition) (2025), pp. 501719-501719
Open Access
R. Pichler, Nils C. H. van Creij, José Daniel Subiela, et al.
Actas Urológicas Españolas (English Edition) (2025), pp. 501719-501719
Open Access
Cell membrane sialome machinery and regulation of receptor tyrosine kinases in gliomas: The functional relevance and therapeutic perspectives
Patrycja Jastrząb, Halina Car, Przemysław Wielgat
Biomedicine & Pharmacotherapy (2025) Vol. 184, pp. 117921-117921
Closed Access
Patrycja Jastrząb, Halina Car, Przemysław Wielgat
Biomedicine & Pharmacotherapy (2025) Vol. 184, pp. 117921-117921
Closed Access
Activation of FGFR genes by genetic and epigenetic alterations in uterine leiomyomas
Vilja Jokinen, Aurora Taira, Åsa Kolterud, et al.
BJC Reports (2025) Vol. 3, Iss. 1
Open Access
Vilja Jokinen, Aurora Taira, Åsa Kolterud, et al.
BJC Reports (2025) Vol. 3, Iss. 1
Open Access
Targeting fibroblast growth factor receptor (FGFR) with inhibitors in head and neck cancers: Their roles, mechanisms and challenges
Daowen Luo, Sirinart Kumfu, Nipon Chattipakorn, et al.
Biochemical Pharmacology (2025) Vol. 235, pp. 116845-116845
Closed Access
Daowen Luo, Sirinart Kumfu, Nipon Chattipakorn, et al.
Biochemical Pharmacology (2025) Vol. 235, pp. 116845-116845
Closed Access
Genetic Rearrangements in Brain Tumors: A View from NTRK
Javier A. Jacobo, Nicolle Wagner-Gutiérrez, Jorge Aristizábal, et al.
IntechOpen eBooks (2025)
Closed Access
Javier A. Jacobo, Nicolle Wagner-Gutiérrez, Jorge Aristizábal, et al.
IntechOpen eBooks (2025)
Closed Access
Targeting USP8 causes synthetic lethality through degradation of FGFR2 in ARID1A-deficient ovarian clear cell carcinoma
Ryosuke Saito, Makoto Fukushima, Mariko Sasaki, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Ryosuke Saito, Makoto Fukushima, Mariko Sasaki, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations
Yasuaki Uemoto, Chang-Ching Lin, Bingnan Wang, et al.
Cancer Letters (2025), pp. 217668-217668
Closed Access
Yasuaki Uemoto, Chang-Ching Lin, Bingnan Wang, et al.
Cancer Letters (2025), pp. 217668-217668
Closed Access
Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion
Nadja Ballin, A. Ott, Olga Seibel-Kelemen, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Nadja Ballin, A. Ott, Olga Seibel-Kelemen, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Advancements and challenges in biomarker testing for tumors of the luminal gastrointestinal tract: current practice guidelines and emerging markers
A. Hein, Erika Hissong
Diagnostic histopathology (2025)
Closed Access
A. Hein, Erika Hissong
Diagnostic histopathology (2025)
Closed Access
Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer
Lewis Au, J. Collin, John M. Mariadason
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1117-1117
Open Access | Times Cited: 4
Lewis Au, J. Collin, John M. Mariadason
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1117-1117
Open Access | Times Cited: 4
Preclinical evidence that fibroblast growth factor receptor pathway inhibition by BGJ398 enhances small cell lung cancer response to chemotherapy
Yingying Shen, Yan Jiang, Junyao Wu, et al.
Anti-Cancer Drugs (2025)
Closed Access
Yingying Shen, Yan Jiang, Junyao Wu, et al.
Anti-Cancer Drugs (2025)
Closed Access
